Unpacking The $2.2Tn Stimulus Act: Boosts To Medtech And Diagnostics To Fight Coronavirus
Executive Summary
A $2.2tn coronavirus stimulus package signed into law by President Trump on 27 March will distribute billions of dollars to federal agencies – including the FDA, the CDC and the FEMA – to hasten approvals of new diagnostics, medical ventilators, respirators and other medtech supplies, conduct more testing of potential COVID-19 patients, and quickly distribute medical supplies where needed most.
You may also be interested in...
FDA Introduces ‘Proactive‘ Resilient Supply Chain Program To Reduce Future Device Shortages
The US FDA’s Resilient Supply Chain Program (RSCP) will be housed in the agency’s Office of Strategic Partnerships and Technology Innovation and aims to reduce future supply chain shortages by applying lessons learned during the pandemic.
Congressional Action Needed To Protect Device Supply Chain, FDA’s Woodcock Says
The US FDA needs enhanced authorities as well as increased funding to track and prevent device shortages, acting commissioner Janet Woodcock argues.
US House Energy & Commerce Committee Lays Out Medtech Agenda, Membership, For 2021 Congress
The House E&C committee and its subpanels will address coronavirus testing, FDA device regulation and cybersecurity during the upcoming 117th Congress.